Drugmaker Alkermes beats Q2 revenue estimates, keeps FY ouitlook
Overview
Alkermes Q2 2025 revenue of $390.7 mln beats analyst expectations
GAAP net income for Q2 2025 was $87.1 mln with diluted EPS of $0.52
Revenue growth driven by strong performance of proprietary products
Outlook
Alkermes reiterates 2025 financial expectations as per Feb. 12 press release
Result Drivers
PROPRIETARY PRODUCT SALES - Strong performance across Vivitrol, Aristada, and Lybalvi drove revenue growth
MEDICAID UTILIZATION - Gross-to-net favorability from Medicaid adjustments contributed to revenue increase
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | $390.70 mln | $341.60 mln (15 Analysts) |
Q2 EPS | $0.52 | ||
Q2 Net Income | $87.10 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 12 "strong buy" or "buy", 5 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Alkermes Plc is $42.00, about 37.7% above its July 28 closing price of $26.15
The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago
Press Release:
